G8879 Clinically node negative (t1n0m0 or t2n0m0) invasive breast cancer

Short descriptor: Node neg inv brst cncr

⚠ Terminated HCPCS Level II 2026
Terminated Code
G8879 was terminated as of 2017-12-31 and should not be reported for dates of service after that date. This page is retained for historical reference.
Open G8879 in the app →

Look up G8879 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.

G8879 is the HCPCS Level II code for Clinically node negative (t1n0m0 or t2n0m0) invasive breast cancer (2026). It belongs to Section G — Procedures / Professional Services (Temporary). Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Not separately priced by Part B.

Classification & CMS Attributes

Medicare Coverage
Carrier judgment (code C)
Part B Pricing
Not separately priced by Part B (indicator 00)
Type of Service
Medical care
Effective Date
2018-01-01
Termination Date
2017-12-31
2026 Maintenance
No change this year

References

Cite This Page

Reference G8879 with the canonical source and edition:

G8879 — Clinically node negative (t1n0m0 or t2n0m0) invasive breast cancer. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/G8879

Canonical URL: https://icd10codingpro.com/hcpcs-codes/G8879

Related Codes in Section G

← G8878 Sent lymph node biopsy G8880 → Sen lym p node biop not perf
G8875 Breast cancer dx min invsive G8876 Doc reas no min inv dx G8877 No brst cncr dx min invasive G8878 Sent lymph node biopsy G8880 Sen lym p node biop not perf G8881 Brst cncr stage > t1n0m0 G8882 No sent lymph node biopsy G8883 Rev, comm, track, doc biopsy G8884 Doc reas biopsy not review G8885 No rev, comm, track biopsy
Browse all HCPCS Level II sections →
Reviewed by Prajwal Shrestha, CPC, CRC
Certified Professional Coder (CPC) and Certified Risk Adjustment Coder (CRC) · AAPC Member ID 01997614 · About · Editorial policy · Content last reviewed: 2026-01-01

Get HCC Mappings, Clinical Summaries, and More

Access premium features including HCC risk adjustment, FDA drug indications, AI coding assistant, and comprehensive clinical context.

Start Free Trial